Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-21-012423

Options or other derivatives

  • Chief Commercial Officer acquired 135,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Hanley Jr. Michael Conick · Chief Commercial Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2021-02-17 Grant or award : show line 1 in the form Employee Stock Option (right to buy) +135,000 135,000 D
Loading xslF345X03/doc4.xml…